Is AxoGen, Inc. (AXGN) a Buy, Sell, or Hold?
NASDAQ : AXGN
AxoGen, Inc.
$38.72 USD
-$0.05 (-0.13%)
- Volume
- 1.06M
- Average Volume
- 1.28M
- Market Capitalization
- $2.06B
- P/E Ratio
- -61.25
- Dividend Yield
- 0.00%
- Price Target
- $49.00
- Year High
- $46.95
- Year Low
- $11.25
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.10
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Michael D. Dale |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Current Symbol | AXGN |
| CUSIP | 05463X106 |
| CIK | 0000805928 |
| Web | https://www.axogeninc.com |
| Phone | 386 462 6800 |
| Currency | USD |
| Employees | 622 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.08 |
| Payout Ratio | 0.00 |
| Current Ratio | 7.10 |
| Quick Ratio | 5.33 |
| Cash Ratio | 3.18 |
Sales & Book Value
| Annual Sales | $225.21M |
| Price / Sales | 8.65 |
| Cash Flow | 0.17 |
| Price / Cash Flow | 230.50 |
| Price / Book | 8.16 |
Price Target and Rating
| Average Stock Price Forecast | $49.00 |
| High Stock Price Forecast | $50.00 |
| Low Stock Price Forecast | $40.00 |
| Forecast Upside/Downside | -20.98% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 19 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.34 |
| Trailing P/E Ratio | -61.25 |
| PEG Ratio | 0.23 |
| P/E Growth | 0.23 |
| Net Income | -$15.7M |
| Net Margin | -13.21% |
| Pretax Margin | -13.21% |
| Return on Equity | -20.74% |
| Return on Assets | -10.87% |
Financials Score
| AltmanZ Score | 27.91 |
| Piotroski Score | 6.00 |
| Working Capital | 158.7M |
| Total Assets | 289.49M |
| Ebit | -16.85M |
| Market Cap | 2.1B |
| Total Liabilities | 44.68M |
Poll Results
About AxoGen, Inc. (NASDAQ:AXGN) Stock
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged perip ... heral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
2026-07-15 07:00:00
ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
2026-07-15 07:00:00
ALACHUA, Fla. and TAMPA, Fla. , July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026.
AxoGen, Stock Of The Day, Offers Entry After Bullish Rebound
2026-06-05 14:25:58
AxoGen, Stock Of the Day, is flashing a buy signal. Ten out of 10 analysts are bullish about AxoGen after strong earnings and raised 2026 guidance.
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
2026-05-14 11:07:07
AxoGen NASDAQ: AXGN President and CEO Michael Dale said the company's growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified.
2026-05-13 18:00:46
Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
2026-04-30 07:00:00
ALACHUA, Fla. and TAMPA, Fla.
Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
2026-04-28 17:41:31
Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
AxoGen (AXGN) Q1 Earnings Lag Estimates
2026-04-28 09:16:41
AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.02 per share a year ago.
Frequently Asked Questions
-
What is the current AxoGen, Inc. (AXGN) stock price?
-
AxoGen, Inc.(NASDAQ:AXGN) stock price is $38.72 in the last trading session. During the trading session, AXGN stock reached the peak price of $46.95 while $11.25 was the lowest point it dropped to. The percentage change in AXGN stock occurred in the recent session was --0.13% while the dollar amount for the price change in AXGN stock was -$0.05.
-
AXGN's industry and sector of operation?
-
The NASDAQ listed AXGN is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of AXGN?
-
Harold D. Tamayo | Vice President of Finance & Investor Relations
Jens Schroeder Kemp | Chief Marketing Officer
Rick Ditto | Vice President of Global Health Economics, Reimbursement & Policy
Erick DeVinney | Chief Innovation Officer
Doris Quackenbush | Vice President of Sales -
How many employees does AXGN have?
-
Number of AXGN employees currently stands at 622. AXGN operates from 13631 Progress Boulevard, Alachua, FL 32615, US.
-
Link for AXGN official website?
-
Official Website of AXGN is: https://www.axogeninc.com
-
How do I contact AXGN?
-
AXGN could be contacted at phone #386 462 6800 and can also be accessed through its website. AXGN operates from 13631 Progress Boulevard, Alachua, FL 32615, US.
-
How many shares of AXGN are traded daily?
-
The average number of AXGN shares traded daily for last 3 months was 1.28M.
-
What is the market cap of AXGN currently?
-
The market value of AXGN currently stands at $2.06B with its latest stock price at $38.72